These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 19639316

  • 1. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Ferlini C, Danesi R, Scambia G, Del Tacca M.
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
    [Abstract] [Full Text] [Related]

  • 2. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
    Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R.
    Cancer Res; 2006 Apr 01; 66(7):3928-35. PubMed ID: 16585222
    [Abstract] [Full Text] [Related]

  • 3. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
    Giovannetti E, Mey V, Loni L, Nannizzi S, Barsanti G, Savarino G, Ricciardi S, Del Tacca M, Danesi R.
    Pharmacol Res; 2007 Apr 01; 55(4):343-9. PubMed ID: 17296311
    [Abstract] [Full Text] [Related]

  • 4. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M.
    Neoplasia; 2010 Oct 01; 12(10):807-17. PubMed ID: 20927319
    [Abstract] [Full Text] [Related]

  • 5. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M, Pach R, Kulig P, Legutko J, Kulig J.
    Pancreas; 2017 Oct 01; 46(5):684-689. PubMed ID: 28196013
    [Abstract] [Full Text] [Related]

  • 6. Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.
    Toffalorio F, Giovannetti E, De Pas T, Radice D, Pelosi G, Manzotti M, Minocci D, Spaggiari L, Spitaleri G, Noberasco C, Catania C, Boselli S, Danesi R, de Braud F.
    Pharmacogenomics J; 2010 Jun 01; 10(3):180-90. PubMed ID: 19901957
    [Abstract] [Full Text] [Related]

  • 7. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
    Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y.
    Br J Cancer; 2007 Feb 12; 96(3):457-63. PubMed ID: 17224927
    [Abstract] [Full Text] [Related]

  • 8. Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
    Yoon KA, Woo SM, Hong EK, Jung MK, Park WS, Bae K, Han SS, Kim TH, Koh YH, Park SJ, Lee WJ.
    Oncology; 2015 Feb 12; 89(6):345-50. PubMed ID: 26418006
    [Abstract] [Full Text] [Related]

  • 9. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S, Ohuchida K, Mizumoto K, Fujita H, Egami T, Yu J, Toma H, Sadatomi S, Nagai E, Tanaka M.
    Anticancer Res; 2008 Feb 12; 28(4B):2205-12. PubMed ID: 18751396
    [Abstract] [Full Text] [Related]

  • 10. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ, Wang WX, Lin L, Song ST.
    Zhonghua Zhong Liu Za Zhi; 2010 Jan 12; 32(1):17-21. PubMed ID: 20211060
    [Abstract] [Full Text] [Related]

  • 11. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL.
    Gastroenterology; 2012 Sep 12; 143(3):664-674.e6. PubMed ID: 22705007
    [Abstract] [Full Text] [Related]

  • 12. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
    Nakamura J, Kohya N, Kai K, Ohtaka K, Hashiguchi K, Hiraki M, Kitajima Y, Tokunaga O, Noshiro H, Miyazaki K.
    Int J Oncol; 2010 Oct 12; 37(4):845-52. PubMed ID: 20811706
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
    Lansakara-P DS, Rodriguez BL, Cui Z.
    Int J Pharm; 2012 Jun 15; 429(1-2):123-34. PubMed ID: 22425885
    [Abstract] [Full Text] [Related]

  • 14. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
    Fisher SB, Fisher KE, Patel SH, Lim MG, Kooby DA, El-Rayes BF, Staley CA, Adsay NV, Farris AB, Maithel SK.
    Cancer; 2013 Jan 15; 119(2):454-62. PubMed ID: 22760605
    [Abstract] [Full Text] [Related]

  • 15. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
    Mori R, Ishikawa T, Ichikawa Y, Taniguchi K, Matsuyama R, Ueda M, Fujii Y, Endo I, Togo S, Danenberg PV, Shimada H.
    Oncol Rep; 2007 May 15; 17(5):1201-5. PubMed ID: 17390066
    [Abstract] [Full Text] [Related]

  • 16. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
    Murata A, Amano R, Yamada N, Kimura K, Yashiro M, Nakata B, Hirakawa K.
    World J Surg Oncol; 2013 May 27; 11():117. PubMed ID: 23710668
    [Abstract] [Full Text] [Related]

  • 17. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T.
    Surgery; 2013 Apr 27; 153(4):565-75. PubMed ID: 23253379
    [Abstract] [Full Text] [Related]

  • 18. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
    Sasaki H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T.
    Br J Cancer; 2014 Sep 23; 111(7):1275-84. PubMed ID: 25032731
    [Abstract] [Full Text] [Related]

  • 19. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
    Skrypek N, Duchêne B, Hebbar M, Leteurtre E, van Seuningen I, Jonckheere N.
    Oncogene; 2013 Mar 28; 32(13):1714-23. PubMed ID: 22580602
    [Abstract] [Full Text] [Related]

  • 20. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
    Fisher SB, Patel SH, Bagci P, Kooby DA, El-Rayes BF, Staley CA, Adsay NV, Maithel SK.
    Cancer; 2013 Jan 15; 119(2):445-53. PubMed ID: 22569992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.